Allogene Therapeutics announced a CEO transition with Zachary Roberts set to succeed David Chang as president and CEO on July 1. Roberts, currently EVP of R&D and Chief Medical Officer at the off-the-shelf cell therapy company, will also join the board. Chang, an Allogene co-founder who has led the company for eight years, will remain on the board following the change. The leadership shuffle comes as off-the-shelf cell therapies and next-generation allogeneic platforms continue to face demanding clinical and manufacturing execution standards. The move signals an internal continuity of clinical and development focus through Roberts’ background in R&D and medical leadership. For investors and partners, the transition reduces uncertainty about operational control while the company executes its clinical and pipeline milestones. In the near term, the market will likely watch whether Roberts changes how Allogene prioritizes trials, manufacturing scalability, and partnerships.